Drug intelligence / Profile preview

dabigatran + rivaroxaban

Development stage: Unknown
Lead developer: University Hospital, Grenoble
Modality: Small Molecules
Administration: Oral

Overview

This entry refers to the sequential administration of dabigatran and rivaroxaban in a clinical trial context, specifically a Phase 4 crossover study (NCT01427608) conducted by the University Hospital, Grenoble. Dabigatran is a direct thrombin (Factor IIa) inhibitor, while rivaroxaban is a direct Factor Xa inhibitor. The study aimed to evaluate the ex-vivo reversal of their anticoagulant effects using various hemostatic agents, such as prothrombin complex concentrate (PCC), recombinant activated coagulation factor VII, and activated prothrombin-complex (FEIBA) for dabigatran, and a specific decoy (FXa-GLAless) for rivaroxaban. Both drugs are primarily indicated for the prevention and treatment of venous thromboembolism (VTE) and stroke prevention in patients with non-valvular atrial fibrillation.

Other names: dabigatran etexilate + rivaroxaban

Targets

F2 (Thrombin)F10 (Factor Xa)

Beyond the preview

Go deeper on dabigatran + rivaroxaban.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dabigatran + rivaroxaban.

Explore the full profile